

Applicants: Reiter, et al.
U. S. Serial No.: 09/855,632
Filed: May 14, 2001
Page: 2

In the Office Action, the Examiner required restriction under 35 U.S.C. §121 to one of the following groups:

- Group I: Claim 1, drawn to an antibody which binds to PSCA;
- Group II: Claims 53-69, drawn to an anti-idiotypic antibody; and
- Group III: Claims 70-86, drawn to a method of inducing an immune response.

Applicants hereby elect the invention of Group I, without traverse since special status has been granted on the parent application, and in order to expedite prosecution of the subject application. As set forth below, claim 1 is canceled and new claims 87-93 that correspond to the subject matter of Group I are added.

Please amend the subject application as follows.

IN THE CLAIMS:

Please cancel claims 1 and 53-86, without prejudice to pursue the subject matter of these claims in a related application.

(Please add new claims 87-93 as follows:

--87. (new) A monoclonal antibody which specifically binds to PSCA of SEQ ID NO.

2.--

--88. (new) The monoclonal antibody of claim 87, which specifically binds to the extracellular domain of PSCA of SEQ ID NO. 2.--

Applicants: Reiter, et al.
U. S. Serial No.: 09/855,632
Filed: May 14, 2001
Page: 3

G. J. Reiter
--89. (new) A monoclonal antibody of claim 87, which is a human antibody.--

B. W.
--90. (new) The monoclonal antibody of claim 87, which is a chimeric antibody. --

--91. (new) An antibody of claim 87, which binds a portion of Prostate Stem Cell Antigen (PSCA) protein of SEQ ID NO. 2, wherein the portion is selected from the group consisting of:

- a. amino acid residues 2 through 50 as described in SEQ ID NO:2;
- b. amino acid residues 85 through 123 as described in SEQ ID NO:2;
- c. amino acid residues 46 through 109 as described in SEQ ID NO:2;
- d. amino acid residues 18 through 98 as described in SEQ ID NO:2;
- e. amino acid residues 22 through 99 as described in SEQ ID NO:2;
- f. amino acid residues 21 through 50 as described in SEQ ID NO:2;
- g. amino acid residues 46 through 85 as described in SEQ ID NO:2;
- h. amino acid residues 50 through 64 as described in SEQ ID NO:2;
- i. amino acid residues 67 through 81 as described in SEQ ID NO:2;
- j. amino acid residues 21 through 99 as described in SEQ ID NO:2;
- k. amino acid residues 71 through 82 as described in SEQ ID NO:2;
- l. amino acid residues 85 through 99 as described in SEQ ID NO:2;
- m. amino acid residues 18 through 50 as described in SEQ ID NO:2;
- n. amino acid residues 46 through 98 as described in SEQ ID NO:2; and
- o. amino acid residues 85 through 98 as described in SEQ ID NO:2.--

--92. (new) An Fab, F(ab')2 or Fv fragment of a monoclonal antibody of claim 87.--

--93. (new) A hybridoma which produces the monoclonal antibody of claim 87. --